Ardelyx (NASDAQ:ARDX) Releases Quarterly Earnings Results

Ardelyx (NASDAQ:ARDX) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03, Briefing.com reports. Ardelyx had a negative return on equity of 41.65% and a negative net margin of 41.36%. The company had revenue of $73.20 million during the quarter, compared to analyst estimates of $55.03 million. During the same quarter in the previous year, the firm earned ($0.08) earnings per share. Ardelyx’s revenue was up 228.3% on a year-over-year basis.

Ardelyx Trading Up 10.0 %

Shares of NASDAQ:ARDX traded up $0.55 during midday trading on Friday, hitting $6.05. 11,161,505 shares of the stock traded hands, compared to its average volume of 5,618,301. Ardelyx has a one year low of $3.16 and a one year high of $10.13. The stock has a market capitalization of $1.41 billion, a PE ratio of -21.11 and a beta of 0.83. The company has a quick ratio of 4.36, a current ratio of 4.53 and a debt-to-equity ratio of 0.66. The business’s 50 day moving average is $6.12 and its two-hundred day moving average is $7.43.

Insider Buying and Selling at Ardelyx

In other news, CEO Michael Raab sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $5.64, for a total transaction of $169,200.00. Following the transaction, the chief executive officer now directly owns 1,260,463 shares of the company’s stock, valued at $7,109,011.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, insider Robert Ora Felsch sold 207,988 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $8.81, for a total value of $1,832,374.28. Following the completion of the transaction, the insider now owns 95,947 shares of the company’s stock, valued at approximately $845,293.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 30,000 shares of Ardelyx stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $5.64, for a total value of $169,200.00. Following the sale, the chief executive officer now owns 1,260,463 shares in the company, valued at $7,109,011.32. The disclosure for this sale can be found here. Insiders sold 494,170 shares of company stock valued at $3,752,676 in the last 90 days. Insiders own 5.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. StockNews.com raised shares of Ardelyx from a “sell” rating to a “hold” rating in a report on Wednesday. Piper Sandler lowered Ardelyx from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $7.00 in a research note on Tuesday, July 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ardelyx in a research report on Thursday, June 20th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Ardelyx in a research report on Thursday, July 18th. Finally, Leerink Partnrs restated an “outperform” rating on shares of Ardelyx in a report on Friday, April 5th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.94.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.